Abstract
Liver cancer is one of the leading causes of cancerous deaths worldwide. At present, the treatment of hepatocellular carcinoma (HCC) remains to be a problem globally. Liushenwan (LSW), an ancient Chinese medicine previously used to treat localized infections, was recently reported to possess anticancer activity. Here in this study, we aim to examine the effect of LSW-ET (LSW-ET is the supernatant fraction of LSW from ultrasound assisted ethanol extraction) in prevention and treatment on nanodiethylnitrosamine- (nanoDEN-) induced HCC in mice. In nanoDEN-induced HCC mice treated with LSW-ET by oral (po) or intragastric gavage (ig), we observed an alleviation of serum ALT and AST levels, amelioration in histopathological stainings, and an inhibition in liver tumor growth. In addition, compared with the nanoDEN group, downregulation of multiple pivotal factors (COX-2, β-catenin, PCNA, and HMGB-1) was observed in LSW-ET-po and LSW-ET-ig groups. Taken together, the delivery of LSW-ET by oral could be a potential prevention and treatment of liver cancer.
Highlights
Liver cancer, called hepatocellular carcinoma (HCC), has been and would remain to be one of the leading causes of cancerous deaths worldwide nowadays and in the near future [1]
To explore the effect of LSW-ET on liver cancer in vivo, a model induced by nanoDEN was employed
The results showed that the inflammatory infiltration in the nanoDEN group was significantly increased at the thirtieth week compared with the control group, and the degree of inflammation in the liver tissues of mice treated with LSW-ET group (LSWET-ig group: 2.18 ± 0.13; LSW-ET-po group: 1.89 ± 0.18) was decreased, suggesting an anti-inflammatory effect of LSWET on liver
Summary
Called hepatocellular carcinoma (HCC), has been and would remain to be one of the leading causes of cancerous deaths worldwide nowadays and in the near future [1]. In China particular, liver diseases affect approximately 300 million people, which contributes much to the global burden of liver diseases [2]. A large fraction of these patients would probably progress into liver cancer at advanced stages due to late diagnoses [3]. Large variability of treatment choices and disease-relate survival confirmed such heterogeneity. A so-called “best” choice for patients with HCC could be quite hard [4]. Alternative agents with better efficacy and less detriment for the management (prevention and treatment included) of HCC are urgently needed [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
